In connection with the ongoing Global Coalition for Adaptive Research international registrational clinical study for glioblastoma multiforme (GBM) in which Kintara Therapeutics, Inc. is participating in all three patient subtypes, GCAR has announced that the study has screened over 1,000 patients and that enrollment rates for the study are 3 to 4 times greater than traditional GBM studies according to GCAR, with active sites averaging 0.75 to 1 patient per site per month. Based on continued dialogue with GCAR in connection with the study, the Company has determined that it will not disclose graduation from stage 1 (safety and efficacy: 100-150 patients) to stage 2 (confirmatory: 50 additional patients). As a result of the accelerated enrollment rate, the Company expects to announce top line data from the Kintara arm of the study around the end of calendar year 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3 USD | +8.50% |
|
+11.07% | +76.89% |
1st Jan change | Capi. | |
---|---|---|
+76.89% | 1.66Cr | |
+16.61% | 12TCr | |
+17.75% | 11TCr | |
+17.23% | 2.59TCr | |
-24.11% | 1.93TCr | |
-18.56% | 1.62TCr | |
-18.47% | 1.56TCr | |
-47.75% | 1.46TCr | |
+57.35% | 1.43TCr | |
+5.62% | 1.4TCr |
- Stock Market
- Equities
- KTRA Stock
- News Kintara Therapeutics, Inc.
- GCAR Screens Over 1,000 Patients for GBM